Compare SCD & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCD | CYPH |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.8M | 321.1M |
| IPO Year | N/A | 2019 |
| Metric | SCD | CYPH |
|---|---|---|
| Price | $14.67 | $1.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 59.7K | ★ 13.5M |
| Earning Date | 01-01-0001 | 11-16-2026 |
| Dividend Yield | ★ 9.63% | N/A |
| EPS Growth | N/A | ★ 103.87 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $590.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.79 | $0.49 |
| 52 Week High | $16.18 | $4.19 |
| Indicator | SCD | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 40.12 | 38.19 |
| Support Level | N/A | $0.65 |
| Resistance Level | $15.53 | $3.42 |
| Average True Range (ATR) | 0.33 | 0.35 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 0.00 | 8.27 |
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.